Novartis Financial Results – Q3 2021

Novartis announced the company’s financial results for the third quarter of 2021.

Media contacts

Find contacts at Novartis for media and journalist inquiries from the general and individual contacts.

Narrow photography of a man using a tablet

Media library

Browse and download multimedia resources including images, videos, infographics and more.

Latest news

Dec 06, 2021

Media Update

Bilateral transaction between Novartis and Roche successfully closed

Dec 02, 2021

Media Release

Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms

Nov 08, 2021

Media Update

Novartis presents positive Phase III results for Cosentyx® in children with active enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) at ACR 2021

All News

Stories

Our research redefines the way we understand disease and develop medicines. Discover the people and stories that make it possible.

Novartis Annual Review 2020

The Annual Review explains who we are and what we do, and highlights our progress against the company’s five strategic priorities in 2020.

A young girl sits at a health clinic in Sikasso, Mali.

Environmental, Social and Governance

Novartis aims to hold itself to the highest standards of sustainability and ethical business practices.

#NovartisNews

Tweets from the Media Relations team

Follow @NovartisNews

Transmission electron microscopic image of an isolate from a case of COVID-19

Novartis COVID-19 Information Center

Novartis is responding to the coronavirus disease (COVID-19) outbreak. The information center provides a central hub for news, guidance and resources.

Live Magazine

Live is the in-house magazine of Novartis which is now available in a digital format. Explore stories, podcasts and more from across the company.

Novartis Gene Therapies Global Managed Access Program

Novartis Gene Therapies recommits to Global Managed Access Program for 2021 so that children around the world can benefit from SMA treatment who otherwise would not have access to Zolgensma.

Subscribe

Get the latest news and updates from Novartis directly to your inbox.

Learn More